Instrument Inactif

Communiqués Neuropathix, Inc.

Actions

NPTX

US64132Q1094

Recherche biotechnologique et médicale

Communiqués

23/05/22	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
25/04/22	Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021	PU
15/04/22	NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
25/03/22	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
12/11/21	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
28/09/21	NEUROPATHIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
06/08/21	NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
20/07/21	Neuropathix : Neuropathix, Inc.	AQ
13/05/21	NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
06/05/21	Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology	GL
30/03/21	NEUROPATHIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
17/03/21	NEUROPATHIX, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
23/02/21	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
25/01/21	Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead	GL
19/01/21	Neuropathix : Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant	AQ
12/01/21	Neuropathix : Appoints World-Renowned Pain Management Clinician Dr. Daniel Richman to the Company’s Scientific Advisory Board	AQ
21/12/20	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
21/12/20	Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate	GL
26/11/20	Cannabinoid series: a CBD-inspired molecule to increase bioavailability	AQ
19/11/20	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
19/11/20	Neuropathix : Signs Binding Letter of Intent to Acquire Anticonvulsant – Neuroprotective Intellectual Property	AQ
19/11/20	Neuropathix, Inc. Signs Binding Letter of Intent to Acquire Anticonvulsant – Neuroprotective Intellectual Property	GL
12/11/20	NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
12/11/20	Neuropathix : Reveals Visual Identity to Coincide With Its Mission for Socially Responsible Pain Management	AQ
12/11/20	Neuropathix, Inc. Reveals Visual Identity to Coincide With Its Mission for Socially Responsible Pain Management	GL